Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

2Q Revenues: $5.8 billion (+6%)

2Q Earnings: $1.5 billion (+108%)*

YTD Reveneus: $11.2 billion (+3%)

YTD Earnings: $3 billion (+44%)

Comments: Zocor sales were $990 million, down 14% due to loss of marketing exclusivity. Singulair sales reached $950 million, up 30%. Rotateq sales were $31 million for the quarter. The Merck/Schering-Plough partnership reported global sales of Zetia and Vytorin reached $973 million as compared to $507 million in 2Q2005. R&D expenses were $1.2 billion for the quarter, up 24%, including $296 million recorded in the quarter for acquired research resulting from the GlycoFi acquisition. The company received product approvals for Gardasil and Zostavax in the quarter.

*Results reflect restructuring costs and a credit of $7 million related to separations as well as gains on the sales of facilities associated with the company’s restructuring program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters